Cover Image
市場調查報告書

EpiCast Report:乳癌的流行病學預測

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 290455
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:乳癌的流行病學預測 EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023
出版日期: 2014年09月10日 內容資訊: 英文 70 Pages
簡介

全球主要9個國家(美國、法國、德國、義大利、西班牙、英國、日本、巴西、中國)的乳癌的發病數,預測到2022年將增加到129萬件(年平均增加率4.4%)。

本報告提供全球主要9個國家的乳癌相關整體概要,提供危險因子概要與全球趨勢,流行病學預測,流行病學報告,疾病趨勢分析,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因子和共生病症
    • 乳癌·BRCA1/2遺傳基因變異的家族病史會擴大風險
    • 生殖荷爾蒙因子對風險的影響
    • 文明病的因素增加患者的死亡率
    • 篩檢計劃減少患者的死亡率
  • 全球趨勢
  • 預測手法
    • 所使用的資訊來源
    • 未使用的資訊來源
    • 預測的前提條件與手法
  • 乳癌的流行病學預測:發病數
    • 發病數
    • 發病數:各年齡
    • 發病數:停經狀態別
    • 發病數:診斷時階段別
    • 發病率:年齡標準化
  • 乳癌的流行病學預測:患病數量
    • 患病數量
    • 患病數量:各年齡
    • 患病數量:停經狀態別
    • 患病數量:各荷爾蒙受體類型
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Prolonged exposure to endogenous and exogenous sex hormones, gene mutations, a family history of breast cancer, overweight and obesity, physical inactivity, a sedentary lifestyle, high alcohol consumption, early age at menarche (<12 years), late age at menopause (>55 years), and clinical factors, such as biopsy-confirmed atypical hyperplasia, and having a high breast tissue and bone density are all risk factors for breast cancer.

GlobalData epidemiologists forecast that the number of diagnosed incident cases of breast cancer in women in the 8MM is expected to grow to 1.21 million cases in 2023 at a rate of 4.23% per year during the forecast period. The number of five-year diagnosed prevalent cases in the 8MM is expected to increase by 43.0% over the next decade to 5.12 million cases in 2023.

GlobalData's forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research's (IARC's) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC's Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Another strength of this analysis is that GlobalData epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.

Scope

  • The Breast Cancer (HER2-, HER2+) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for breast cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). In addition, the report also includes a 10-year forecast for the incident and the five-year prevalent cases of breast cancer in women segmented by age (20 to =85 years), natural menopausal status, cancer stage at diagnosis (local, regional, distant, unstaged), and hormone receptor subtypes: ER+ and/or PR+, HER2-; ER-, PR-, HER2+; ER+ and/or PR+, HER2+; and ER-, PR-, HER2- (triple negative).
  • The breast cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
  • Quantify patient populations in the global breast cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups, menopausal status, cancer stage, and hormone receptor subtypes that present the best opportunities for breast cancer therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. A family history of breast cancer and BRCA1/2KKK gene mutations significantly increase the breast cancer risk
    • 3.2.2. Reproductive hormonal factors influence the risk of breast cancer
    • 3.2.3. Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients
    • 3.2.4. Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Prevalence and Survival
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Breast Cancer (2013-2023) - Diagnosed Incident Cases
    • 3.5.1. Diagnosed Incident Cases of Breast Cancer
    • 3.5.2. Diagnosed Incident Cases of Breast Cancer by Age
    • 3.5.3. Diagnosed Incident Cases of Breast Cancer by Menopausal Status
    • 3.5.4. Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis
    • 3.5.5. Age-Standardized Diagnosed Incidence Rate of Breast Cancer
  • 3.6. Epidemiological Forecast for Breast Cancer (2013-2023) - Diagnosed Prevalent Cases
    • 3.6.1. Five-Year Diagnosed Prevalent Cases of Breast Cancer
    • 3.6.2. Five-Year Diagnosed Prevalent Cases by Menopausal Status
    • 3.6.3. Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Selected Major Risk Factors and Comorbidities for Breast Cancer
  • Table 2: Breast Cancer Mortality Attributable to Lifestyle-Related Risk Factors
  • Table 3: 8MM, Current Status and Plans of Large-Scale Breast Cancer Screening Programs
  • Table 4: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004**
  • Table 5: Conversion of Common Staging Systems for Breast Cancer Used in the Forecast
  • Table 6: 8MM, Sources of the Breast Cancer Diagnosed Incidence Data Used in the Epidemiological Forecast
  • Table 7: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Table 8: 8MM, Diagnosed Incident Cases of Breast Cancer by Age, Women, N (Row %), 2013
  • Table 9: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N (Row %), 2013
  • Table 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013
  • Table 11: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Table 12: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013

List of Figures

  • Figure 1: 8MM, Age-Standardized Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Cases per 100,000 Population, 2008
  • Figure 2: 8MM, Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Rate per 100,000 Population, 2008
  • Figure 3: US, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 1975-2009
  • Figure 4: 5EU, Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Cases per 100,000 Population, 1975-2010
  • Figure 5: Japan, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 2003-2008
  • Figure 6: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004**
  • Figure 7: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Figure 8: 8MM, Diagnosed Incident Cases of Breast Cancer, by Age, Women, N, 2013
  • Figure 9: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N, 2013
  • Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013
  • Figure 11: 8MM, Age-Standardized Diagnosed Incidence Rate of Breast Cancer, Ages ≥20 Years, Women, Cases per 100,000 Population, 2013
  • Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N, 2013
  • Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013
Back to Top